ProHeart 12 keeps the focus on year-long heartworm compliance: full analysis

ProHeart 12 is back in the spotlight through sponsored veterinary media coverage that frames the product around four themes: tasty, tough, broad, and fast. Behind that messaging is a familiar clinical proposition: a single injection of extended-release moxidectin that provides 12 months of heartworm prevention in dogs, with the added benefit of hookworm treatment coverage on label. While the Veterinary Practice News piece is promotional, the underlying product claims line up with FDA approval documents and the current prescribing information. (veterinarypracticenews.com)

The product isn’t new. FDA’s Center for Veterinary Medicine approved ProHeart 12 on July 2, 2019, for dogs 12 months of age and older for prevention of heartworm disease caused by Dirofilaria immitis for 12 months. That approval built on the earlier history of ProHeart 6, including safety concerns that led to a voluntary Risk Minimization Action Plan. FDA says ProHeart 12 was added to that existing RiskMAP framework, which includes restricted distribution, training and certification for veterinary personnel, informed consent, and enhanced pharmacovigilance measures intended to preserve access while managing risk. (fda.gov)

The key clinical selling point is compliance. In the pivotal FDA-reviewed field study, 297 client-owned dogs received ProHeart 12, and FDA reported the studies demonstrated 100% effectiveness in preventing heartworm disease for one year. The open-access Parasites & Vectors efficacy paper describes two laboratory studies and a multisite U.S. field study, and notes that dogs in the injectable arm were dosed in-clinic on Day 0 and Day 365 by certified users. The same paper argues that clinic-administered prevention offers more reliable documentation of adherence and creates built-in opportunities for heartworm testing and preventive review. (fda.gov)

Safety and administration remain part of the conversation. Current labeling says ProHeart 12 is indicated only for dogs 12 months and older, and that dogs should be tested for existing heartworm infection before administration. Product labeling and FDA materials also note hypersensitivity-type reactions and injection-site reactions among potential adverse events, which is why the certification and risk-management infrastructure remains attached to the product. A separate safety study published in Parasites & Vectors concluded the formulation was well tolerated in the evaluated studies, with observed injection-site findings generally characterized as non-adverse in margin-of-safety work. (animaldrugsatfda.fda.gov)

Industry and expert context reinforces why Zoetis keeps pushing the compliance angle. The American Heartworm Society says the number of annual preventive doses sold in the U.S. has declined despite growth in the pet population, and its latest incidence mapping continues to show heartworm as a national issue rather than a regional one. AAHA’s recent coverage of the newest AHS map quoted AHS leadership saying most infections in dogs that receive preventives are tied to lapses in compliance, such as missed doses or administration errors, rather than resistance alone. That framing supports the market logic for a once-yearly, clinic-administered option. (heartwormsociety.org)

There’s also a broader parasitology backdrop. CAPC continues to recommend annual antigen and microfilariae testing for all dogs, including those on prevention, and lists injectable moxidectin among the available macrocyclic lactone options. Research published after approval has suggested injectable moxidectin can perform strongly against at least some macrocyclic lactone-resistant heartworm strains, though that shouldn’t be read as a standalone solution to resistance pressure. For clinicians, the more practical takeaway is that consistent, documented prevention still matters more than theoretical efficacy advantages if pet parents aren’t able to maintain monthly dosing. (capcvet.org)

Why it matters: For veterinary teams, ProHeart 12 sits at the intersection of preventive medicine, workflow, and client communication. It can reduce missed-dose risk, improve certainty around compliance, and anchor annual preventive visits, but it also requires proper patient selection, pre-administration testing, informed consent, and staff certification. In clinics serving pet parents who struggle with monthly adherence, that tradeoff may be worthwhile. In others, the conversation may center on flexibility, cost, and comfort with injectable risk management. (fda.gov)

What to watch: Watch for continued emphasis on heartworm incidence trends, annual testing guidance, and whether more clinics adopt long-acting injectable prevention as part of a broader compliance strategy rather than as a simple product substitution. (heartwormsociety.org)